Europe Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2017

Europe Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2017

Fore Pharma announced the results of its Pancreatic Cancer patients study in a new report ‘Europe Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Pancreatic Cancer epidemiology, Pancreatic Cancer diagnosed patients, and Pancreatic Cancer treatment rate for EU5 pharmaceutical markets. The study measures key indicators such as prevalence of Pancreatic Cancer derived from epidemiological analysis, percentage of patients diagnosed with Pancreatic Cancer, and percentage of patients treated with a therapy.

The study helps executives estimate Pancreatic Cancer market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Pancreatic Cancer prevalence, Pancreatic Cancer diagnosis rate, and Pancreatic Cancer treatment rate for the period 2016 - 2025. The information is presented by leading geographies including Germany, France, Spain, Italy, and UK. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.

Key Features of the Report:

• Pancreatic Cancer Patient Flow
• Pancreatic Cancer Prevalence
• Pancreatic Cancer Diagnosed Patients
• Pancreatic Cancer Treated Patients